94662-39-2

Usage

InChI:InChI=1/C20H25N3O3S2/c24-28(25)19-15-27-14-18(19)20(22-28)21-9-4-12-26-17-7-5-16(6-8-17)13-23-10-2-1-3-11-23/h5-8,14-15H,1-4,9-13H2,(H,21,22)

Upstream product

• 73279-03-5 3-[4-(1-piperidinylmethyl)phenoxy]-1-propanamine 
• 94662-49-4 3-(methylthio)thieno<3,4-d>isothiazole 1,1-dioxide 
• 59337-79-0 thieno(3,4-d)-1,2-thiazol-3(2H)-one 1,1-dioxide 
• 94662-48-3 thieno[3,4-d]isothiazole-3(2H)-thione 1,1-dioxide 

Relevant academic research and scientific papers

Syntheses and Gastric Acid Antisecretory Properties of the H2-Receptor Antagonist N-propyl>thienoisothiazol-3-amine 1,1-Dioxide and Related Derivatives

The synthesis and gastric acid antisecretory properties of several N-substituted thienoisothiazol-3-amine 1,1-dioxides and analogues are described.Two of the more potent compounds, N-propyl>thienoisothiazol-3-amine 1,1-dioxide (6a) and N-propyl>thienoisothiazol-3-amine 1,1-dioxide (6b), showed greater potencies as H2-receptor antagonist (in vitro) than ranitidine.They also had potent gastric acid antisecretory activities in vivo, inhibiting basal acid secretion in the rat (6a, 6b), histamine-stimulated acid secretion in the dog (6a, 6b), and food-stimulated acid secretion in the dog (6a).These were selected for further pharmacological evaluation.

Precursors of benzo- and thieno-fused heterocyclic anti-ulcer agents

A process for preparing certain benzo- and thieno-fused heterocyclic compounds having H2 -receptor antagonist and antisecretory activity, which comprises the amide reduction of N-substituted carbamoyl-containing benzo- or thieno-fused heterocyc